Abstract
Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechincontaining extracts, many consumers of cardiovascular drugs assume these products as a “natural” and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that “more-is-better”.
Keywords: Green tea, herb-drug interaction, dietary-drug interaction, catechins, simvastatin, warfarin, nadolol, cardiovascular drugs.
Current Pharmaceutical Design
Title:Overview of Green Tea Interaction with Cardiovascular Drugs
Volume: 21 Issue: 9
Author(s): Jose P. Werba, Shingen Misaka, Monica G. Giroli, Shizuo Yamada, Viviana Cavalca, Keisuke Kawabe, Isabella Squellerio, Federica Laguzzi, Satomi Onoue, Fabrizio Veglia, Veronika Myasoedova, Kazuhiko Takeuchi, Eisuke Adachi, Naoki Inui, Elena Tremoli and Hiroshi Watanabe
Affiliation:
Keywords: Green tea, herb-drug interaction, dietary-drug interaction, catechins, simvastatin, warfarin, nadolol, cardiovascular drugs.
Abstract: Sensitive to the massive diffusion of purported metabolic and cardiovascular positive effects of green tea and catechincontaining extracts, many consumers of cardiovascular drugs assume these products as a “natural” and presumably innocuous adjunctive way to increase their overall health. However, green tea may interfere with the oral bioavailability or activity of cardiovascular drugs by various mechanisms, potentially leading to reduced drug efficacy or increased drug toxicity. Available data about interactions between green tea and cardiovascular drugs in humans, updated in this review, are limited so far to warfarin, simvastatin and nadolol, and suggest that the average effects are mild to modest. Nevertheless, in cases of unexpected drug response or intolerance, it is warranted to consider a possible green tea-drug interaction, especially in people who assume large volumes of green tea and/or catechin-enriched products with the conviction that “more-is-better”.
Export Options
About this article
Cite this article as:
Werba P. Jose, Misaka Shingen, Giroli G. Monica, Yamada Shizuo, Cavalca Viviana, Kawabe Keisuke, Squellerio Isabella, Laguzzi Federica, Onoue Satomi, Veglia Fabrizio, Myasoedova Veronika, Takeuchi Kazuhiko, Adachi Eisuke, Inui Naoki, Tremoli Elena and Watanabe Hiroshi, Overview of Green Tea Interaction with Cardiovascular Drugs, Current Pharmaceutical Design 2015; 21 (9) . https://dx.doi.org/10.2174/1381612820666141013135045
DOI https://dx.doi.org/10.2174/1381612820666141013135045 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design Myocardial Infarction with Non Obstructive Coronary Atherosclerosis: A Case Report
New Emirates Medical Journal Alzheimer’s Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome
Current Neuropharmacology Biomarkers in Cardiomyopathies and Prediction of Sudden Cardiac Death
Current Pharmaceutical Biotechnology High-Density Lipoprotein-Mediated Anti-Atherosclerotic and Endothelial-Protective Effects: A Potential Novel Therapeutic Target in Cardiovascular Disease
Current Pharmaceutical Design Patent Selections
Recent Patents on Cardiovascular Drug Discovery Carbonyl-Scavenging Drugs & Protection Against Carbonyl Stress-Associated Cell Injury
Mini-Reviews in Medicinal Chemistry Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Current Pharmacological Treatment of Pulmonary Arterial Hypertension
Current Clinical Pharmacology A Review of the Evidence for a Neuroendocrine Link Between Stress, Depression and Diabetes Mellitus
Current Diabetes Reviews Multifunctional Nanoparticles, Nanocages and Degradable Polymers as a Potential Novel Generation of Non-Invasive Molecular and Cellular Imaging Systems
Recent Patents on Nanotechnology Beta-Blockers in the Treatment of Dilated Cardiomyopathy: Which is the Best?
Current Pharmaceutical Design Peripheral Biomarkers to Assess Suicide Risk
Current Psychiatry Reviews Postmenopausal Hypertension: Insights from Rat Models
Current Hypertension Reviews Gender Disparity in Pediatric Diseases
Current Molecular Medicine Recent Patents Regarding Essential Oils and the Significance of their Constituents in Human Health and Treatment
Recent Patents on Anti-Infective Drug Discovery Potential Prognostic, Diagnostic and Therapeutic Markers for In-stent Reocclusion in Advanced Age Patients After Coronary Stenting
Current Pharmaceutical Design Development and Characterization of Spray Dried Microparticles for Pulmonary Delivery of Antifungal Drug
Current Drug Delivery Propitious Profile of Peppery Piperine
Current Molecular Pharmacology